StartupHistory

An open directory of startups through time

Public records · dated sources
Free to read. Free to reuse.

Company records / dermavant.com

Dermavant

Dermavant (dermavant.com): 8 changes recorded in its website history since February 2011. Homepage last checked 5 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

  1. HeadlineBetween and
    BeforeDermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
    AfterOrganon, here for her health

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagecurrent websiteHistorical capture not publicly availableLink to observation
  2. ComplianceBetween and

    Now states FDA APPROVED compliance on its homepage.

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation
  3. HeadlineBetween and
    BeforeDermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in…
    AfterDermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation
  4. HeadlineBetween and
    BeforeDermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine
    AfterDermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in…

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation
  5. HeadlineBetween and
    BeforePatient‑Focused Innovation
    AfterDermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation
  6. HeadlineBetween and
    BeforeRobust Pipeline
    AfterPatient‑Focused Innovation

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation
  7. HeadlineBetween and
    BeforeDermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer
    AfterRobust Pipeline

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation
  8. HiringBetween and

    Added a careers page.

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation

First recorded website

Observed 2 February 2011

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

dermavant.com

Homepage

Listed prices
$4.99 / mo · $1.19 / mo

archived pageLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

  1. Seen November 2026 · 1 capture · latest observed messagingOrganon, here for her health

    Organon is a global health care company dedicated to making a world of difference for women, their families and the communities they care for.

    This wording observed 5 November 2026.

    current websiteHistorical capture not publicly available
  2. Seen July 2024 · 1 captureDermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan

    Dermavant uses science with breakthrough innovations and challenging the standard of care in immuno-dermatology to treat chronic skin conditions.

    This wording observed 1 July 2024.

    archived page
  3. Seen September 2023 · 1 captureDermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

    Dermavant Sciences is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics in immuno-dermatology.

    This wording observed 26 September 2023.

    archived page
  4. Seen January 2022 · 1 captureDermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine

    Dermavant Sciences is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics in immuno-dermatology.

    This wording observed 3 January 2022.

    archived page
  5. Seen January 2021 · 1 capturePatient‑Focused Innovation

    This wording observed 19 January 2021.

    archived page
  6. Seen April 2020 · 1 captureRobust Pipeline

    This wording observed 9 April 2020.

    archived page
  7. February 2011 – January 2019 · 3 capturesDermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer

    Home

    This wording observed 19 January 2019.

    archived page
    Inspect 3 captures in this group
    • 2 February 2011 · dermavant.com archived page
    • 18 September 2017 · DERMAVANT SCIENCES archived page
    • 19 January 2019 · Dermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer archived page
Summary of the record · AI-written

Written by an AI model on 7 November 2026 from the dated observations above; this is not the date the changes happened; each point links to the changes it rests on.

Dermavant shifts homepage messaging to “Organon, here for her health”

Dermavant’s site has moved from product trial and approval news toward a new homepage headline referencing Organon, while also adding FDA APPROVED language. Earlier messaging focused on clinical results and approvals for tapinarof.

  • Between September 2023 and July 2024, Dermavant changed its homepage headline to “Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan”. [6]
  • Between September 2023 and July 2024, the company homepage began stating FDA APPROVED compliance. [7]
  • Between July 2024 and November 2026, Dermavant changed its homepage headline to “Organon, here for her health”. [8]
  • Reading: The move from headlines about tapinarof approvals to “Organon, here for her health” may suggest a shift in how Dermavant is positioning itself or its relationship with Organon on its homepage. [6][8]

Cite this record

StartupHistory, “Dermavant” company record, https://startuphistory.org/c/dermavant.com

Machine-readable: /c/dermavant.com.json. How changes are found: method.